GlycoMimetics is well funded with a total of over $60 million raised to date in three rounds of financing. In each round, the syndicate of investors was led by New Enterprise Associates. Additional investors include Genzyme Ventures, Alliance Technology Ventures, Anthem Capital, the Novartis Venture Fund, PTV Sciences, and the State of Maryland.
In 2011, GlycoMimetics entered a worldwide license agreement with Pfizer for GlycoMimetics’ lead product candidate, GMI-1070, for all indications. The agreement provides potential value to GlycoMimetics of over $340 million, plus tiered, double-digit royalties.
New Enterprise Associates
New Enterprise Associates, Inc. (NEA) is a leading venture capital firm focused on helping entrepreneurs build transformational businesses across multiple stages, sectors and geographies. With approximately $13 billion in committed capital, NEA invests in information technology, healthcare and energy technology companies at all stages in a company’s lifecycle, from seed stage through IPO. The firm’s long track record includes more than 175 portfolio company IPOs and more than 290 acquisitions. In the U.S., NEA has offices in the Washington, D.C. metropolitan area; Menlo Park, California; and New York City. In addition, New Enterprise Associates (India) Pvt. Ltd. has offices in Bangalore and Mumbai, India and New Enterprise Associates (Beijing), Ltd. has offices in Beijing and Shanghai, China. For additional information, visit http://www.nea.com.
Established in 2001 to help Genzyme Corporation achieve its strategic and financial goals, Genzyme Ventures invests directly in private early-stage companies with promising new products and breakthrough science. Genzyme Ventures has also invested as a limited partner (LP) in other life science–focused venture funds and continues to maintain strong relationships with the venture capital community through these investments. Today, Genzyme Ventures is a $100 million fund with a portfolio of eight direct equity investments in a variety of promising private companies. As a limited partner we also maintain active relationships with eight venture firms that position Genzyme as a partner in the broader health care innovation landscape.
Alliance Technology Ventures
Alliance Technology Ventures (ATV) is a venture capital firm focused on private company investments in the semiconductor, communication component and life science industries. Beyond financial support, an investment from ATV brings knowledgeable guidance and a hands-on commitment to success. All of ATV’s investment professionals have been directly involved in building early-stage companies and leverage that experience to help our portfolio companies grow through the progressive stages of research, development and commercialization.
Founded in 1993, ATV is based in Sarasota, FL, with venture partners in Boston, MA and Palo Alto, CA. With over $250 million under management, we are actively seeking to invest in companies that fit our investment criteria.
Anthem Capital Management
Founded in 1994, Anthem Capital Management, Inc. provides early-stage venture capital for rapidly growing businesses exclusively in the Mid-Atlantic region. Anthem focuses on those industries that comprise the core of the entrepreneurial and emerging growth companies within that region – Software, Telecommunications, Life Sciences/Medicine and Industrial Technology. Anthem brings over 100 years of combined business experience, half of which is focused on venture capital investing and managing rapidly growing businesses.
The Novartis Venture Fund
Novartis has been funding new business projects that show exemplary entrepreneurial spirit in future-oriented health science areas since 1996. The Novartis BioVenture Fund focuses its investments in product- and platform-focused biotech, pharmaceutical and healthcare companies at all stages, with an emphasis on the United States.
The Novartis Venture Funds (NVF), established in 1996 as an evergreen fund, has grown into one of the largest corporate life sciences venture funds. With approximately $800M in committed capital we make six to ten new investments each year and manage a portfolio of over 65 private companies in the United States, Europe, and Asia. As a financially driven corporate life science investor, NVF invests in companies which have the potential to change existing clinical practice while providing significant patient benefit. The primary interest is in the development of novel therapeutics, platforms, medical devices, and diagnostics, and we continue to explore new business concepts that will be critical to patient care in the future. The Fund invests in all stages of company development, and is committed to our heritage of investing in start-up and pre-clinical development stage companies. The Novartis Venture Fund team of ten investment professionals is located in Cambridge, MA and Basel, Switzerland and brings together extensive experience in pharmaceutical R&D, biotechnology, and venture capital.
PTV Sciences, L.P.
PTV Sciences is a healthcare venture capital and growth equity firm focused on enabling healthcare entrepreneurs and global innovation. Founded in 2003, PTV has a highly collaborative team of 27 professionals, deeply experienced as investors and operators of life science companies, focused on enabling industry leading companies and investing in extraordinary people in the healthcare and life sciences sector, including medical devices, biotechnology, pharmaceuticals, and diagnostics. PTV Sciences has offices in Austin and Houston, TX.
Maryland Department of Business and Economic Development
DBED’s mission is to create, attract, and retain jobs while promoting Maryland’s vibrant cultural economies. Maryland’s 440 life science companies and 50 research-intense federal institutes make it a leader in the global life science sector. The BioMaryland 2020 Strategic Plan, a $1.3 billion investment in the state’s life sciences industry over 10 years, will attract and grow the bioscience opportunities of tomorrow in Maryland. Recognized by the Milken Institute as top state bioscience development, the bioscience research community annually receives nearly $8 billion in research and development.
Pfizer applies science and its global resources to improve health and well-being at every stage of life. Pfizer strives to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals. Its diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world’s best-known consumer products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with its responsibility as the world’s leading biopharmaceutical company, Pfizer also collaborates with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference.